



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 498 136 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 A2)
INID code(s) 22

(51) Int Cl.7: **A61K 39/00**, A61K 35/14,
A61K 35/28, A61P 35/00

(48) Corrigendum issued on:
13.04.2005 Bulletin 2005/15

(43) Date of publication:
19.01.2005 Bulletin 2005/03

(21) Application number: **04024995.5**

(22) Date of filing: **23.12.1999**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**

(30) Priority: **31.12.1998 US 222011**

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
99968946.6 / 1 141 246

(71) Applicants:
• **HADASIT MEDICAL RESEARCH SERVICES AND
DEVELOPMENT LTD.
91120 Jerusalem (IL)**
• **BAXTER INTERNATIONAL INC.
Deerfield, IL 60015 (US)**

(72) Inventors:
• **Slavin, Shimon
Ein Karem, Jerusalem (IL)**
• **Prigozhina, Tatyana
Rehovot (IL)**

(74) Representative: **Schmitz, Jean-Marie
Denemeyer & Associates S.A.
P.O. Box 1502
1015 Luxembourg (LU)**

Remarks:

This application was filed on 22 - 10 - 2004 as a
divisional application to the application mentioned
under INID code 62.

(54) **Non-myeloablative tolerogenic treatment**

(57) The present invention relates to the use of an-
tigens of a donor mammal in the manufacture of a med-
icament for inducing tolerance in a host mammal to a
graft from said donor mammal, said donor mammal be-
ing non-syngeneic to said host mammal, wherein:

- (a) said antigens are administered to said host
mammal;
- (b) an immunosuppressive agent is administered to
said host mammal in a non-myeloablative regimen
sufficient to decrease said host mammal's function-
al T-lymphocyte population;
- (c) said graft is transplanted into said host mammal,

wherein steps (a), (b) and (c) are performed on the
same day; and

(d) a non-myeloablative dose of lymphocytotoxic or
tolerizing agent is administered to said host mam-
mal to selectively eliminate said host mammal's
lymphocytes responding to said antigens.

EP 1 498 136 A8